Unambiguously Identify Your Protein Target with Immuno-MRM Assays
Precision oncology with next-generation immuno-MRM Assays
Genomic analyses do not always reliably predict the expression and functionality needed for protein-targeted therapies.
CellCarta’s proteomic services provide you with comprehensive options for protein quantification in clinical samples.
Our immuno-MRM platform is uniquely able to capture the advantages of quantitative mass spectrometry.
Utilizing target-specific affinity reagents and immuno-MRM proof-of-concept data, our platform enables highly flexible assays for oncology clinical trials.
Superior Protein Quantification with CellCarta's Immuno-MRM Assays
With our immuno-MRM assays, our clients obtain the advantage of protein quantification via multiple reaction monitoring (MRM) technology to confidently quantify specific target fragments in clinical samples.
Why choose immuno-MRM assays for clinical application?
- Superior multiplexed and quantitative protein measurements
- High sensitivity, specificity, and selectivity
- Unambiguous target identification
- Ability to detect protein post-translational modifications
- Harmonized assays through internal standards
Immuno-MRM assays for exploratory research and clinical trials
What is CellCarta’s advantage?
- Over 400 anti-peptide antibodies with an emphasis on immuno-oncology and ras/MAPK signaling
- Further validation for immuno-MRM panels to support clinical endpoints
- Complementary immunohistochemistry assays for single-cell resolution and subcellular localization
- Complementary flow cytometry analysis for immune-induced changes
Dr. Paulovich’s leading expertise
With the exclusive acquisition of Precision Assays assets in 2022, we provide the latest in immuno-MRM panels.
Dr. Paulovich, founder of Precision Assays, is a pioneer in multiplex, quantitative protein biomarker measurements by mass spectrometry.
Dr. Paulovich’s research has advanced the tools for quantifying human proteins, setting best-in-class standards to support precision medicine studies in cancer-specific protein expression analysis in a variety of matrices from FFPE cancer tissue biopsies to clinical serum-based samples.